BiomaterialsBioprintingMedical ResearchPress Releases

CELLINK establishes R&D lab in AstraZeneca’s BioVentureHub for Oncology Research

Stay up to date with everything that is happening in the wonderful world of AM via our LinkedIn community.


CELLINK, the Gothenburg-based creator of one of the world’s first universal bioinks and a leading bioprinter developer and provider, is setting up a new lab at BioVentureHub that will enable the company to develop better kidney, heart, liver and lung tissue models for use in pharmaceutical development.

“We are very happy to establish an R&D lab in AstraZeneca’s BioVentureHub. It gives us a unique opportunity to collocate with, and tap into, the power of AstraZeneca’s world-class scientists and facilities, as well as with the other exciting life science companies in the hub. Surrounded by experts in cardiovascular, metabolic, respiratory and oncology diseases, it’s a truly inspiring environment in which to develop our future offering of bioprinting technologies.” Erik Gatenholm, (co-founder and CEO, CELLINK)

Located in the BioVentureHub, at the heart of AstraZeneca’s R&D Gothenburg site, the new lab will be staffed by a team of four scientists and researchers. They will focus on developing opportunities for customers and partners to bioprint using any type of cells relevant to the targeted applications.

The BioVentureHub continues to grow. With CELLINK onboard, and after 8 new companies joined in 2017, there are currently 25 companies and 1 academic group in the BioVentureHub.

“CELLINK is developing exciting 3D bioprinting technologies that are enabling new ways to study biological systems and develop better treatments. Delivering on our ambition to facilitate interactions between drug, device, diagnostic and digital health companies, Erik and the CELLINK team will undoubtedly add significant value to the innovation experiment we are building here at the BioVentureHub.” Magnus Björsne, (CEO, AstraZeneca BioVentureHub)

AstraZeneca established the BioVentureHub in 2014 as an open innovation ecosystem to further strengthen competitiveness and dynamism in the Scandinavian life science industry. Based on an innovative public-private partnership model and located at the heart of AstraZeneca Gothenburg, the BioVenturehub gives emerging biotech/medtech companies and academic groups from Sweden and abroad a unique opportunity to co-locate with – and tap into – the power of AstraZeneca’s world-class scientists and state-of-the-art lab facilities and infrastructure, and with each other.

Research 2021
Ceramic AM Market Opportunities and Trends

This market study from 3dpbm Research provides an in-depth analysis and forecast of the ceramic additive ma...

3D Printing Media Network

3D Printing Media Network is the editorial branch of 3D Printing Business Directory. It was set up to provide the latest industry news and opinions to a global audience of professionals.

Related Articles

Back to top button

We use cookies to give you the best online experience. By agreeing you accept the use of cookies in accordance with our cookie policy.

Privacy Settings saved!
Privacy Settings

When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.

These cookies are necessary for the website to function and cannot be switched off in our systems.

In order to use this website we use the following technically required cookies
  • wordpress_test_cookie
  • wordpress_logged_in_
  • wordpress_sec

Decline all Services
Accept all Services



Join industry leaders and receive the latest insights on what really matters in AM!

This information will never be shared with 3rd parties

I’ve read and accept the privacy policy.*